Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 465 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma September 6, 2022 Opinion: ‘The UK must be more ambitious than just clearing the... May 24, 2021 Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC June 6, 2025 ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ February 10, 2019 Load more HOT NEWS Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death Why Wearing Comfortable Clothes During Cancer Treatment Matters
